DDD Partners LLC Takes $817,000 Position in Pfizer Inc. (NYSE:PFE)

DDD Partners LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 32,237 shares of the biopharmaceutical company's stock, valued at approximately $817,000.

Other large investors also recently bought and sold shares of the company. Clarity Asset Management Inc. purchased a new stake in Pfizer during the 4th quarter worth about $27,000. Gould Capital LLC increased its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. North Capital Inc. purchased a new stake in Pfizer during the 1st quarter worth about $28,000. Bernard Wealth Management Corp. purchased a new stake in Pfizer during the 4th quarter worth about $30,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Redburn Atlantic dropped their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Jefferies Financial Group increased their price objective on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. BMO Capital Markets reduced their price target on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. Finally, The Goldman Sachs Group lifted their price objective on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $28.55.

Pfizer Price Performance

Pfizer stock traded down $0.02 during mid-day trading on Wednesday, hitting $24.59. 44,174,346 shares of the company were exchanged, compared to its average volume of 41,947,842. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The business's 50 day simple moving average is $23.95 and its two-hundred day simple moving average is $24.77. The company has a market capitalization of $139.79 billion, a P/E ratio of 17.82, a PEG ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business's revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.82 earnings per share. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.00%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.